EXTON, Pa.–(BUSINESS WIRE)– Six months post-launch of Vertex’s Incivek (telapravir) and Merck/Roche’s Victrelis (boceprevir), specialists report a significant increase in usage of both products in their genotype 1 HCV patients compared to one month post-launch. Incivek remains the market share leader, though the gap in preference for Incivek over Victrelis is beginning to narrow compared to previous waves of research. Surveyed hepatologists reported using significantly more Incivek than infectious disease specialists.
Not all Genotype 1 patients are being treated with this new standard of care, however. Patient resistance to being re-treated with any interferon regimen is still quite high. On the flip side, 49% of the surveyed physicians do report trial for the protease inhibitors in other genotypes despite a lack of supportive clinical data. With regards to products in development, surveyed physicians report the greatest familiarity with Pharmasett’s PSI-7977, an investigational nucleoside polymerase inhibitor that is currently being tested in a phase 3 clinical trial without the use of interferon.